A Review of Treatment in Non-small-cell Lung Cancer
Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases. For patients with early-stage disease, surgery followed by adjuvant chemotherapy is the optimal treatment. For patients with locally advanced disease, the standard approach is chemoradiotherapy, since it offers a small but statistically significant prolongation in survival compared with the sequential approach. It should be noted, however, that this approach is associated with significant toxicity and it only applies to patients with good performance status. For patients with metastatic disease, chemotherapy represents the cornerstone of treatment and results in a median survival of approximately 10 months. Recently, the addition of bevacizumab or cetuximab to chemotherapy doublets and the use of gefitinib and erlotinib has improved the outcome in selected patients with advanced NSCLC. Hopefully, advances in understanding the molecular biology of cancer and mechanisms of tumourigenesis will facilitate the discovery and development of novel ‘targeted agents’ and will further improve outcomes for these patients.
Share this Article
Related Content In Lung Cancer
Pafolacianine: A Diagnostic Agent to Identify Lung Cancer Lesions in Adults with Known or Suspected Lung Cancer
touchREVIEWS in Oncology & Haematology. 2023;19(1):2-3 DOI: https://doi.org/10.17925/OHR.2023.19.1.2
Accurately detecting lung tumours and their margins is important for disease outcomes.1,2 However, detection is challenging due to the use of minimally invasive surgery and current localization techniques, such as computed tomography (CT)-guided and endobronchial interventions, which add significantly to procedure time and risk of complications.3 Intraoperative imaging using a targeted agent to optically fluoresce cancerous cells may address these problems, in addition to locating […]
Amivantamab: A Potent Novel EGFR/c-MET Bispecific Antibody Therapy for EGFR-mutated Non-small Cell Lung Cancer
touchREVIEWS in Oncology & Haematology. 2021;17(1):42-47 DOI: https://doi.org/10.17925/OHR.2021.17.1.42
Cancer treatment has expanded rapidly in recent years as advancements in the fields of tumour biology and molecular diagnostics have informed the development of targeted therapies, improving survival in patients with oncogene-addicted cancers with therapeutically relevant molecular lesions. Osimertinib has become the standard-of-care treatment in the USA and elsewhere for classical epidermal growth factor receptor […]
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Patients with Non-small Cell Lung Cancer of Squamous Histology: Focus on Afatinib
touchREVIEWS in Oncology & Haematology. 2021;17(1):36-41 DOI: https://doi.org/10.17925/OHR.2021.17.1.36
The treatment of patients with non-small cell lung cancer (NSCLC) has seen significant advances in the past decade, with the availability of multiple targeted therapy agents for oncogenic-driven non-squamous NSCLC and the advent of immunotherapy that has completely revolutionized the treatment of patients without oncogenic drivers. Consequently, the lives of patients with NSCLC have significantly […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!